Latest enzyme replacement therapy Stories
Former head of rare diseases at Genzyme brings a 20-year track record of delivering successful, innovative products to patients throughout the world PHILADELPHIA, Dec.
- MPS IV A patients and families urge swift, publicly funded access to life-altering drug VIMIZIM(TM) - VANCOUVER, July 7, 2014 /CNW/ - The Canadian Society for Mucopolysaccharide
What causes brain damage and inflammation in severe cases of Gaucher disease?
A genetic condition that attacks multiple organs and usually results in fatal heart problems can be detected using a new MRI technique that was developed at the University of Alberta.
A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.
- A volcanic mudflow.